Monoclonal antibody found to improve COPD outcomes, trial results suggest

The monoclonal antibody treatment dupilumab was found to reduce the annual rate of moderate or severe exacerbations of chronic obstructive pulmonary disease when compared with placebo.
preparing injection
Dupilumab is administered subcutaneously

Shutterstock.com

Dupilumab, a treatment licensed for asthma and eczema, has been found to reduce the rate of acute exacerbations in patients with chronic obstructive pulmonary disease (COPD), study results have shown.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated